ObsEva SA announced a symposium and three oral presentations on linzagolix, an oral GnRH antagonist, at the 7th Society of Endometriosis and Uterine Disorders (SEUD) Congress being held virtually and in Stockholm, Sweden as a hybrid event from December 9-11, 2021. Presentation details are as follows: Title: Recovery of Bone Mineral Density (BMD) after Long Term Treatment with Linzagolix in Women with Endometriosis: Results from a Phase 2b Dose-Ranging Trial. Format: Oral Presentation. Presenter: Jacques Donnez Session Date & Time: Free Communications 1 beginning December 10th at 4:30 p.m. CET. Title: Long Term Efficacy of Linzagolix for Treatment of Heavy Menstrual Bleeding (HMB) due to Uterine Fibroids (UF): 52-Week Results from Two Placebo-Controlled, Randomized, Phase 3 Trials. Format: Oral Presentation. Presenter: Hugh Taylor. Session Date & Time: Free Communications 6 beginning December 10th at 5:30 p.m. CET. Title: Long Term Safety and Tolerability of Linzagolix for Treatment of Heavy Menstrual Bleeding (HMB) due to Uterine Fibroids (UF): 52-Week Results from Two Placebo-Controlled, Randomized, Phase 3 Trials. Format: Oral Presentation. Presenter: Jacques Donnez. Session Date & Time: Free Communications 6 beginning December 10th at 5:30 p.m. CET.